Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX22 + trastuzumab + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HLX22 + trastuzumab + nab-paclitaxel + gemcitabine is a combination therapy being investigated for the first-line treatment of HER2-positive metastatic pancreatic ductal adenocarcinoma. HLX22 is a recombinant humanized monoclonal antibody that targets the extracellular subdomain IV of the human epidermal growth factor receptor 2 (HER2) at an epitope distinct from that of trastuzumab. This allows both antibodies to bind simultaneously to HER2, leading to a dual blockade that synergistically inhibits HER2 signaling and promotes receptor internalization and degradation. The addition of this dual HER2-targeted approach to the standard-of-care chemotherapy regimen of gemcitabine and nab-paclitaxel (GEM-NABP) aims to improve clinical outcomes in patients with HER2-expressing pancreatic malignancies, a population with high unmet medical needs.
- Other names
- HLX22 + trastuzumab + chemotherapyHLX22 + trastuzumab + GEM-NABPHLX22 + trastuzumab + nab-paclitaxel + gemcitabine
02
Targets
TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HLX22 + trastuzumab + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX22 + trastuzumab + nab-paclitaxel + gemcitabine.